title: Three Dimensional Power Doppler evaluation of human endometrium after administration of oxytocine receptor antagonist (OTRa) in an IVF program.
abstract: OBJECTIVE
  To compare endometrial and subendometrial morphological changes and vascularity as measured by 3D Power Doppler sonography, based on a specific scoring system between women subjected or not to oxytocine receptor antagonist (OTRa) during IVF cycles.
  
  
  METHODS
  Twenty-six women were divided into groups according to OTRa (Atosiban tractocide) administration. The first group (control n = 13 women) was examined with 3D Power Doppler 3 days after embryo transfer. The second group (n = 13 women) was administered 7.5 mg intravenous tractocide 2 days after embryo transfer and a 3D Power Doppler was performed after a day.
  
  
  RESULTS
  The control group presented the following ultrasonographic characteristics: (a) echogenic endometrium in all cases, (b) endometrial thickness >7 mm in all cases (84.6%), (c) endometrial volume >2.31 cm(3) in 5 cases (38.5%), (d) abnormal sub-endometrial halo in 3 cases (23.1%), (e) endometrial blood flow in 6 cases (46.2%) and (f) complex vessel's architecture in 2 cases (15.4%). In women who underwent OTRa administration were observed: (a) echogenic endometrium in 1 case (7.7%), triple line endometrium in 12 cases (92.3%), (b) endometrial thickness >7 mm in all cases, (c) endometrial volume >2.31 cm(3) in 11 cases (84.6%), (d) abnormal sub-endometrial halo in 3 cases (23.1%), (e) endometrial blood flow in 11 cases (84.6%) and (f) complex vessel's architecture in 6 cases (46.2%).
  
  
  CONCLUSIONS
  Women who have taken OTRa presented an endometrium with characteristics more predictive of implantation.
authors.affiliation: 1st Department of Obstetrics and Gynecology, Alexandra Hospital, Athens University Medical School, G! Septembriou Street, 10433, Athens, Greece. KKalmantis@hotmail.com
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Kalmantis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Loutradis
authors.forename: Elias
authors.initials: E
authors.lastname: Lymperopoulos
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Beretsos
authors.forename: Ritsa
authors.initials: R
authors.lastname: Bletsa
authors.forename: Aris
authors.initials: A
authors.lastname: Antsaklis
mesh_terms: D000328:Adult; D010064:Embryo Implantation / Q000187:drug effects; D004717:Endometrium / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000187:drug effects*; D005260:Female; D005307:Fertilization in Vitro / Q000187:drug effects*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007247:Infertility, Female / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D011247:Pregnancy; D018873:Pregnancy Rate; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors*; D018608:Ultrasonography, Doppler / Q000379:methods; D014668:Vasotocin / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D006727:Hormone Antagonists; C569600:OXTR protein, human; D018045:Receptors, Oxytocin; C047046:atosiban; D014668:Vasotocin